Serina Therapeutics, Inc. (SER)
↓ Download CSV- Sector Manufacturing
- Incorporated AL
- Fiscal year ends Dec 31
In fiscal 2025, Serina Therapeutics, Inc. reported revenue of $130.0K, up 132.1% from the prior year. The company ran a net loss, with a net margin of -14755.4%. It held $6.95M in total assets against $6.99M in total liabilities.
Key ratios (FY2025)
-18478.5%
Operating margin
-14755.4%
Net margin
+132.1%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $130.0K | $56.0K | $3.15M | $34.0K | $144.0K | $361.0K | $1.73M | $1.40M | $1.40M | — |
| Cost of Revenue | — | — | $40.0K | $13.0K | $19.0K | $26.0K | $244.0K | $364.0K | $168.0K | — |
| Gross Profit | — | — | $102.0K | $21.0K | $125.0K | $335.0K | $1.48M | $1.03M | $1.24M | — |
| Operating Income | -$24.02M | -$17.05M | -$3.13M | -$6.97M | -$7.93M | -$10.10M | -$12.56M | -$11.24M | -$6.66M | — |
| Net Income | -$19.18M | -$11.14M | $5.27M | -$10.46M | -$8.68M | -$10.87M | -$12.15M | -$7.50M | -$6.58M | — |
| EPS (Diluted) | $-1.91 | $-1.51 | $2.36 | $-9.70 | $-0.23 | — | — | — | — | — |
| Total Assets | $6.95M | $6.72M | $8.97M | $3.24M | $3.15M | $3.92M | $7.44M | $10.67M | $9.63M | — |
| Total Liabilities | $6.99M | $6.22M | $4.86M | $20.56M | $15.03M | $9.32M | $4.83M | $2.44M | $1.31M | — |
| Shareholders' Equity | -$37.0K | $508.0K | -$32.29M | -$37.78M | -$11.88M | -$5.40M | $2.62M | $8.23M | $8.32M | -$22.38M |
| Cash & Equivalents | $3.06M | $3.67M | $7.62M | $645.0K | $584.0K | $527.0K | $2.35M | $6.71M | $7.38M | $259.0K |
| Operating Cash Flow | -$17.95M | -$17.14M | -$2.48M | -$5.94M | -$7.86M | -$7.82M | -$10.16M | -$8.00M | -$6.29M | — |
| Capital Expenditures | $59.0K | $22.0K | — | — | — | $20.0K | $641.0K | $21.0K | $1.0K | — |
| Shares Outstanding | 10.77M | 9.42M | 2.41M | 1.08M | 37.94M | 37.69M | 37.65M | 35.83M | 33.75M | — |